Department of Medicine, Cardiology Division, Duke University Medical Center, Durham, NC; Duke Clinical Research Institute, Durham, NC.
Department of Medicine, University of Colorado, Aurora, CO.
Am Heart J. 2019 Jul;213:91-96. doi: 10.1016/j.ahj.2019.04.008. Epub 2019 Apr 25.
Patients considering destination therapy left ventricular assist devices (DT LVAD) often have high comorbid burden but the association between these comorbidities and post-decision outcomes is unknown.
We included subjects in DECIDE-LVAD (NCT02344576), a stepped-wedge multicenter trial of patients considering LVADs, recording comorbidities per INTERMACS protocol. We compared decisional conflict, regret, perceived stress, quality of life (EQ-VAS), depression (PHQ-2), struggle with- and acceptance of illness by comorbid burden and amongst the most common comorbidities.
Of 239 patients, LVAD recipients (n = 164) and non-recipients (n = 75) had a similar proportion with ≥1 comorbidity (70% v. 80%, P = .09). Patients with comorbidities were younger regardless of LVAD implantation status. After adjusting for age, overall and amongst LVAD recipients, patients with ≥1 comorbidity had higher mean decision conflict at baseline (23.2 ± 1.5 vs. 17.4 ± 2.2), and at 6 months, higher stress (13.0 ± 0.6 vs. 10.4 ± 1.0) and struggle with illness (13.3 ± 0.4 vs. 11.1 ± 0.6) than those without comorbidities (P < .05). No difference was noted in decision regret, PHQ-2, EQ-VAS, acceptance of illness and survival overall and amongst LVAD recipients. Of the three most common comorbidities, while patients with pulmonary hypertension had worse decision regret, depression, stress and acceptance of illness at 6-month follow-up than those who did not have pulmonary hypertension, no difference was noted in patients with chronic renal disease or high body mass index.
Patients considering LVAD implantation with comorbidities experience increased decision conflict, stress and struggle with illness. These findings provide insights in the role comorbidities play in patient decision-making and decisional outcomes.
考虑接受终末期心力衰竭左心室辅助装置(destination therapy left ventricular assist devices,DT LVAD)的患者通常合并多种疾病,但这些疾病与决策后结局之间的关系尚不清楚。
我们纳入了 DECIDE-LVAD(NCT02344576)研究中的患者,这是一项考虑接受 LVAD 的患者的多中心、阶梯式随机对照试验,按照 INTERMACS 方案记录合并症。我们比较了合并症负担和最常见合并症之间的决策冲突、后悔、感知压力、生活质量(EQ-VAS)、抑郁(PHQ-2)、与疾病抗争和对疾病的接受程度。
在 239 例患者中,LVAD 接受者(n=164)和非接受者(n=75)的合并症发生率相似(70%比 80%,P=0.09)。无论是否植入 LVAD,合并症患者的年龄均较小。在校正年龄后,整体和 LVAD 接受者中,≥1 种合并症患者的基线决策冲突更高(23.2±1.5 比 17.4±2.2),6 个月时压力更高(13.0±0.6 比 10.4±1.0),与疾病抗争的程度更高(13.3±0.4 比 11.1±0.6)(P<0.05)。在决策后悔、PHQ-2、EQ-VAS、对疾病的接受程度以及整体生存方面,无合并症患者与有合并症患者之间无差异。在三种最常见的合并症中,虽然肺动脉高压患者在 6 个月随访时的决策后悔、抑郁、压力和对疾病的接受程度更差,但与没有肺动脉高压的患者相比,慢性肾脏病或高体重指数患者无差异。
合并症患者在考虑植入 LVAD 时经历了更多的决策冲突、压力和与疾病抗争。这些发现提供了对合并症在患者决策和决策结果中的作用的深入了解。